| abstract |
REFERS TO MACROCICLIC COMPOUNDS OF FORMULA (I) WHERE THE LINE OF POINTS IS AN OPTIONAL DOUBLE LINK BETWEEN ATOMS C7 AND C8; R1 IS HO (C1-C6) ALKYL; R2 IS H O (C1-C6) ALKYL; n IS 3 TO 6. PREFERRED COMPOUNDS ARE: N- [18- [2- (4-ISOPROPYLTIAZOL-2-IL) -7-METOXYQUINOLIN-4-IL-OXI] -2,15-DIOXO-3,14, 16-TRIAZATRICICLO [14.3.0.0 (4,6)] NONADEC-7-ENO-4-CARBONIL] - (CYCLOPROPYL) SULFONAMIDE, N- [17- (2- (4-ISOPROPYLTIAZOL-2-IL) -7-METOXIQUINOLIN -4-IL-OXY) -13-METHYL-2,14-DIOXO-3,13,15-TRIAZATRICYCLO [13.3.0.0 (4,6)] OCTADEC-7-ENO-4-CARBONIL] - (CYCLOPROPYL) SULFONAMIDE , {17- [2- (4-ISOPROPYLTIAZOL-2-IL) -7-METOXYQUINOLIN-4-ILOXI] -2,14-DIOXO-3,13,15-TRIAZATRICICLO [13.3.0.0 (4,6)] OCTADEC -7-ENO-4-CARBONYL} -AMIDE OF CYCLOPROPANOSULPHONIC ACID, AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION THAT MAY ALSO INCLUDE ANOTHER ACTIVE AGENT SUCH AS RITONAVIR. THESE COMPOUNDS ARE INHIBITORS OF HCV PROTEASE NS3 / 4a, BEING USEFUL IN THE TREATMENT OF HEPATITIS C |